Prenatal Screening

Labassure’s Prenatal Screening services offer expectant parents important insights into the health and development of their baby. These blood-based tests are non-invasive and help estimate the risk of chromosomal conditions such as Down syndrome (Trisomy 21), Edwards syndrome (Trisomy 18), and open neural tube defects (ONTDs). Depending on the stage of pregnancy, different screening markers are recommended.

Key Benefits:

Early Risk Detection: Identifies the likelihood of chromosomal abnormalities and neural tube defects during the first and second trimesters.
Non-Invasive: Requires only a maternal blood sample, posing no risk to the fetus.
Supports Timely Decisions: Enables early intervention, counseling, or follow-up diagnostic testing when needed.
Accessible & Widely Accepted: Ideal for routine prenatal care, especially when advanced tests like NIPT are not immediately available.
Customizable Based on Gestational Age: Double, triple, and quadruple marker tests are performed at specific time points to maximize accuracy.
Cost-Effective: Offers a reliable and economical option for screening in both low- and high-risk pregnancies.
Integrates with Ultrasound Findings: Enhances predictive value when combined with nuchal translucency or anomaly scans.

Recommended For:

All pregnant women, especially those who missed early screening
Pregnancies with limited access to first-trimester ultrasound
Women with advanced maternal age
Pregnancies with a family or personal history of birth defects
‍

Labassure's prenatal screening solutions offer an important, risk-free first step in ensuring fetal well-being—guiding appropriate follow-up and supporting peace of mind.

These screening tests do not diagnose a condition but rather assess the likelihood of fetal abnormalities. Abnormal results may warrant further evaluation through NIPT, detailed ultrasound, or invasive testing such as amniocentesis.

Double Marker Test (First Trimester)

Performed between 11–14 weeks of gestation, this test measures free β-hCG and PAPP-A levels in maternal blood. When combined with nuchal translucency (NT) measurement on ultrasound, it provides early risk assessment for chromosomal abnormalities such as Trisomy 21 and Trisomy 18.

Triple Marker Test (Second Trimester)

Conducted between 15–20 weeks of gestation, the triple marker measures AFP (Alpha-Fetoprotein), β-hCG, and Estriol (uE3). It is commonly used when the first-trimester screening was missed and helps evaluate the risk of neural tube defects and chromosomal anomalies.

Quadruple Marker Test

Performed between 15–20 weeks of gestation, this maternal blood test measures Alpha-Fetoprotein(AFP), human chorionic gonadotropin (hCG), unconjugated estriol (uE3), andinhibin-A. The results, when interpreted with maternal age and clinical information, help estimate the risk of chromosomal abnormalities such as Downsyndrome (Trisomy 21), Edwards syndrome (Trisomy 18), and certain neural tube defects

Prenatal Screening

Corporate

Test & Services

Prenatal Screening

Double Marker (Frist Trimester) - PAPP-A, Free βHCG (Roche)

Triple marker Marker (Second Trimester) - AFP, βHCG (Roche), Estriol

Quadraple Marker - AFP, βHCG (Roche), Estriol, Inhibin A

Corporate

Test & Services